Journey Medical Corporation

NasdaqCM:DERM Stock Report

Market Cap: US$112.2m

Journey Medical Future Growth

Future criteria checks 5/6

Journey Medical is forecast to grow earnings and revenue by 79.9% and 24% per annum respectively while EPS is expected to grow by 80.9% per annum.

Key information

79.9%

Earnings growth rate

80.9%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate24.0%
Future return on equityn/a
Analyst coverage

Low

Last updated19 Nov 2024

Recent future growth updates

Recent updates

Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth

Oct 03
Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth

Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden

Sep 14
Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden

Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?

May 06
Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?

Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%

Mar 11
Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%

Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues

Jan 18
Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues

Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Nov 10
Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%

US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results

May 12
US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results

Earnings and Revenue Growth Forecasts

NasdaqCM:DERM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202693-1N/AN/A1
12/31/202577-2N/AN/A4
12/31/202457-23N/AN/A4
9/30/202458-18-28-28N/A
6/30/2024781-8-8N/A
3/31/202480-411N/A
12/31/202379-405N/A
9/30/202380-121318N/A
6/30/202361-39-13-8N/A
3/31/202363-38-20-15N/A
12/31/202274-30-34-14N/A
9/30/202275-41-34-13N/A
6/30/202279-41-291N/A
3/31/202276-46-33-3N/A
12/31/202163-44-12-2N/A
9/30/202159-20-36N/A
6/30/202149-9-3-2N/A
3/31/202145456N/A
12/31/202045545N/A
12/31/201935479N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DERM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: DERM is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DERM is expected to become profitable in the next 3 years.

Revenue vs Market: DERM's revenue (24% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: DERM's revenue (24% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DERM's Return on Equity is forecast to be high in 3 years time


Discover growth companies